Acyclovir Sodium facilitates high antiviral selectivity through a targeted three-step phosphorylation process:

• Selective TK Activation: Acyclovir is converted to acyclovir monophosphate primarily by viral thymidine kinase (TK). This ensures the drug is activated almost exclusively in virus-infected cells, preserving host cell integrity.
• DNA Polymerase Competition: After cellular enzymes further phosphorylate it to acyclovir triphosphate (the active form), it competes with deoxyguanosine triphosphate (dGTP) for incorporation into the viral DNA chain.
• Irreversible Chain Termination: Once incorporated, the lack of a 3'-hydroxyl group on the acyclovir molecule causes immediate obligate chain termination, irreversibly halting viral DNA synthesis and replication.

• Sterile Injectable Manufacturing: Foundational API for intravenous solutions used in severe herpes simplex encephalitis and initial episodes of genital herpes in immunocompromised patients.
• Lyophilized Powder Development: Optimized for high-concentration powder for injection, providing rapid reconstitution and low particulate counts.
• Neonatal & Critical Care: Applied in formulating critical antiviral regimens for neonatal HSV infections and VZV complications.

Acyclovir free base has very low aqueous solubility (approx. 1.3 mg/mL at 25°C). The Sodium salt form significantly increases water solubility (exceeding 100 mg/mL), which is essential for achieving the high concentrations required for effective intravenous bolus or infusion delivery.

Acyclovir Sodium is highly alkaline (pH 10.5-11.5 in solution). It can react with atmospheric carbon dioxide ($CO_{2}$) to form Acyclovir base, which has poor solubility and may precipitate. Nitrogen flushing prevents this reaction, maintaining API clarity and assay integrity.

Guanine is a primary process-related impurity. At Xi'an Tihealth, we utilize multi-stage crystallization and validated HPLC profiling to ensure that Guanine and other related substances remain strictly within USP/EP pharmacopoeial limits (≤0.7% total), ensuring patient safety.

Yes. Our pharmaceutical-grade Acyclovir Sodium features high crystalline consistency and low residual solvents. It is optimized for lyophilization (freeze-drying) processes, resulting in a robust, white porous cake with rapid reconstitution properties.

Yes. We provide a full technical documentation package, including the Certificate of Analysis (COA), Method of Analysis (MOA), Stability Data, and MSDS. We are committed to supporting our partners through international regulatory filings and GMP audits.